Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice T Shaw

Showing results (1-10 of 204) with videos related to

Pageof 21
Sort By:
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancerAlice T Shaw
Clinical Advances in Hematology & Oncology : H&O|January 10, 2018
ALK inhibitors in non-small cell lung cancer: how many are needed and how should they be sequenced?Alice T Shaw
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2011
Targeting anaplastic lymphoma kinase in lung cancerAlice T Shaw, Benjamin Solomon
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2011
Are anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer prognostic, predictive, or both?Benjamin Solomon, Alice T Shaw
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter?Jessica J Lin, Alice T Shaw
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
ALK in lung cancer: past, present, and futureAlice T Shaw, Jeffrey A Engelman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancerJustin F Gainor, Alice T Shaw
The New England Journal of Medicine|June 26, 2014
Ceritinib in ALK-rearranged non-small-cell lung cancerAlice T Shaw, Jeffrey A Engelman
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2017
Fast, Food and Ceritinib in ALK-Positive NSCLCJustin F Gainor, Alice T Shaw
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2010
One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung cancerJoel W Neal, Alice T Shaw
Pageof 21

Showing results (1-10 of 204) with videos related to

Sort By:
Pageof 21
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancerAlice T Shaw
Clinical Advances in Hematology & Oncology : H&O|January 10, 2018
ALK inhibitors in non-small cell lung cancer: how many are needed and how should they be sequenced?Alice T Shaw
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2011
Targeting anaplastic lymphoma kinase in lung cancerAlice T Shaw, Benjamin Solomon
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2011
Are anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer prognostic, predictive, or both?Benjamin Solomon, Alice T Shaw
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter?Jessica J Lin, Alice T Shaw
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
ALK in lung cancer: past, present, and futureAlice T Shaw, Jeffrey A Engelman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancerJustin F Gainor, Alice T Shaw
The New England Journal of Medicine|June 26, 2014
Ceritinib in ALK-rearranged non-small-cell lung cancerAlice T Shaw, Jeffrey A Engelman
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2017
Fast, Food and Ceritinib in ALK-Positive NSCLCJustin F Gainor, Alice T Shaw
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2010
One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung cancerJoel W Neal, Alice T Shaw
Pageof 21